Aeternus Biopharma (Århus, Denmark) a preclinical-stage regenerative biopharma company focused on therapeutics and companion diagnostics for population identification and treatment of the herodotus exceptional longevity master cell, closed a historic $499M Series A financing. Participants include Maximus Ventures, Amplus Capital Partners and Ingens Ventures. The investor syndicate indicated their financing model of placing the total anticipated required capital to support the entire discovery to commercialization process for Aeternus.